中国中医药信息杂志:中医药防治股骨头坏死临床应用现状

2018-07-10 佚名 中国中医药信息杂志

股骨头坏死(ONFH)是骨科较常见的难治性疾患,致残率极高,其发病机制尚不明确。中医药防治ONFH具有独特优势,并逐渐受到重视。本文从ONFH的中医病名、病因病机、辨证分型、临床治疗等方面,综述近年中医药防治ONFH临床应用现状,为该病临床提供参考。

股骨头坏死(ONFH)是骨科较常见的难治性疾患,致残率极高,其发病机制尚不明确。中医药防治ONFH具有独特优势,并逐渐受到重视。本文从ONFH的中医病名、病因病机、辨证分型、临床治疗等方面,综述近年中医药防治ONFH临床应用现状,为该病临床提供参考。

近年来,结合现代科研方法,中医药在治疗ONFH 的研究方面做了大量工作,也取得了一定的成果;而随着精准医疗模式的引入,与其核心个体化精准治疗高度辩证统一的中医学整体观和辨证论治等理论特色及中药作用多系统、多靶点等特点,使中医药在治疗日益高发的ONFH 方面体现出疗效确切、治法多样、不良反应小、应用广泛等明显优势。但与此同时,也应正视中医药防治ONFH 亟待解决的问题:中医药对于早中期ONFH 疗效较好,而对于中晚期ONFH 治疗相关报道甚少;目前尚未形成权威公认的辨证分型,其诊断、治疗及疗效判定尚未标准化;中药治疗ONFH 的作用机制尚未完全阐明,目前对于中药及复方有效成分的研究不甚全面;中医研究ONFH相关循证医学的统计与分析较少且病例观察数及随访时间存在不足,其科学性及说服力受到一定程度的限制。

随着分子生物学的发展,ONFH 相关microRNA等基因的表达逐渐成为研究热点,为中医研究者提供了新思路。应充分把握机遇,深入探索中医药对ONFH相关基因表达的影响,以期为中医药治疗ONFH提供更多理论支持。

原始出处:
李盛华,邓昶,周明旺,等.中医药防治股骨头坏死临床应用现状[J].中国中医药信息杂志,2018,25(6):137-140.DOI:10.3969/j.issn.1005-5304.2018.06.035

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2019-06-09 redcrab
  3. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 millore
  5. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 cathymary
  6. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1669167, encodeId=bfce166916e72, content=<a href='/topic/show?id=3ccb215e0b1' target=_blank style='color:#2F92EE;'>#中医药防治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21570, encryptionId=3ccb215e0b1, topicName=中医药防治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1e7626506004, createdName=makuansheng, createdTime=Mon Nov 26 03:24:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1721850, encodeId=5f871e21850dd, content=<a href='/topic/show?id=01811016363e' target=_blank style='color:#2F92EE;'>#骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101636, encryptionId=01811016363e, topicName=骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cd033099978, createdName=redcrab, createdTime=Sun Jun 09 13:24:00 CST 2019, time=2019-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1835758, encodeId=3dec1835e58b4, content=<a href='/topic/show?id=cfdc22e893f' target=_blank style='color:#2F92EE;'>#临床应用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22789, encryptionId=cfdc22e893f, topicName=临床应用)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 23 10:24:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362896, encodeId=a81c136289618, content=<a href='/topic/show?id=b723414321c' target=_blank style='color:#2F92EE;'>#坏死#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41432, encryptionId=b723414321c, topicName=坏死)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409628, encodeId=fad4140962857, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1529701, encodeId=295b1529e01fc, content=<a href='/topic/show?id=70ff81e9156' target=_blank style='color:#2F92EE;'>#股骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81791, encryptionId=70ff81e9156, topicName=股骨)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d3011964327, createdName=wangyang7962, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584884, encodeId=ba24158488464, content=<a href='/topic/show?id=931581e97ad' target=_blank style='color:#2F92EE;'>#股骨头#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81797, encryptionId=931581e97ad, topicName=股骨头)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0ee217064831, createdName=huagfeg, createdTime=Thu Jul 12 09:24:00 CST 2018, time=2018-07-12, status=1, ipAttribution=)]
    2018-07-12 huagfeg

相关资讯

中医药现代化、生殖健康等12个国家重点研发计划重点专项2018年申报指南

各省、自治区、直辖市及计划单列市科技厅(委、局),新疆生产建设兵团科技局,国务院各有关部门科技主管司局,各有关单位:

山东省副省长孙继业调研中医药工作:提高山东中医药在全国的影响力和竞争力

山东省副省长孙继业到山东省中医药研究院附属医院、山东中医药大学附属医院调研中医药工作。

国家中医药管理局召开局长会议

国家中医药管理局召开局长会议,贯彻落实习近平总书记关于中医药工作的系列重要指示精神,专题听取学习贯彻党的十九大精神、推动中医药事业传承发展8个“重点专题”研究情况汇报,研究部署有关工作。局长于文明主持会议,党组书记、副局长余艳红,副局长马建中、王志勇、闫树江出席会议。

中医药传承创新行动合作项目启动

中医药传承创新行动合作项目启动会暨公立中医院绩效改革与发展论坛在京举办。

河南1000万元支持中医药科研

7月16~20日,河南省中医管理局将开始受理2018年度河南省中医药科学研究专项课题申报。今年,该局增加投入200万元,全年课题立项经费总额达1000万元(含医院配套经费)。

国家中医药管理局党组召开会议

国家中医药管理局党组召开会议,传达学习习近平总书记在全国组织工作会议和中央政治局第六次集体学习上的重要讲话精神,系统学习习近平总书记关于中医药工作的系列重要指示精神,研究贯彻落实措施。国家卫生健康委党组成员、国家中医药管理局党组书记余艳红主持会议。党组成员马建中、王志勇、闫树江出席会议,局长于文明列席会议。